Serological and Clinical Features of Patients with Myasthenia Gravis in North Indian Population

REFERENCES

• Birmanns, B., Brenner, T., Abramsky, O., & Steiner, I. (1991). Seronegative myasthenia gravis: Clinical features, response to therapy and synthesis of acetylcholine receptor antibodies in vitro. Journal of the Neurological Sciences, 102, 184–189.
   PubMedGoogle Scholar
• Blaes, F., Beeson, D., Plested, P., Lang, B., & Vincent, A. (2000). IgG from “seronegative” myasthenia gravis patients binds to a muscle cell line, TE671, but not to human acetylcholine receptor. Annals of Neurology, 47, 504–510.
   PubMedGoogle Scholar
• Brooks, E. B., Pachner, A. R., Drachman, D. B., & Kantor, F. S. (1990). A sensitive rosetting assay for detection of acetylcholine receptor antibodies using BC3H-1 cells: Positive results in ‘antibody-negative’ myasthenia gravis. Journal of Neuroimmunology, 28, 83–93.
   PubMedGoogle Scholar
• De Perrot, M., Liu, J., Bril, V., McRae, K., Bezjak, A., & Keshavjee, S. H. (2002). Prognostic significance of thymomas in patients with myasthenia gravis. The Annals of Thoracic Surgery, 74, 1658–1662.
   PubMed Web of Science ®Google Scholar
• Drachman, D. B., de Silva, S., Ramsay, D., & Pestronk, A. (1987). Humoral pathogenesis of myasthenia gravis. Annals of the New York Academy of Sciences, 505, 90–105.
   PubMedGoogle Scholar
• Giagheddu, M., Puggioni, G., Sanna, G., Tamburini, G., Marrosu, F., Rachele, M. G., (1989). Epidemiological study of myasthenia gravis in Sardinia, Italy (1958–1986). Acta Neurologica Scandinavica, 79, 326–333.
   PubMedGoogle Scholar
• Hoch, W., McConville, J., Helms, S., Newsom-Davis, J., Melms, A., & Vincent, A. (2001). Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nature Medicine, 7, 365–368.
   PubMed Web of Science ®Google Scholar
• Hokkanen, E. (1969). Epidemiology of myasthenia gravis in Finland. Journal of the Neurological Sciences, 9, 463–478.
   PubMedGoogle Scholar
• Lavrnic, D., Jarebinski, M., Rakocevic-Stojanovic, V., Stevic, Z., Lavrnic, S., Pavlovic, S., (1999). Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983–1992). Acta Neurologica Scandinavica, 100, 168–174.
   PubMedGoogle Scholar
• Lefvert, A. K., Bergstrom, K., Matell, G., Osterman, P. O., & Pirskanen, R. (1978). Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenetic implications. Journal of Neurology, Neurosurgery, and Psychiatry, 41, 394–403.
   PubMed Web of Science ®Google Scholar
• Lindstrom, J. M., Seybold, M. E., Lennon, V. A., Whittingham, S., & Duane, D. D. (1976). Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology, 26, 1054–1059.
   PubMed Web of Science ®Google Scholar
• Maggi, G., Casadio, C., Cavallo, A., Cianci, R., Molinatti, M., & Ruffini, E. (1989). Thymectomy in myasthenia gravis. Results of 662 cases operated upon in 15 years. European Journal of Cardio-Thoracic Surgery, 3, 504–509.
   PubMedGoogle Scholar
• Nicholson, G. A., McLeod, J. G., & Griffiths, L. R. (1983). Comparison of diagnostic tests in myasthenia gravis. Clinical and Experimental Neurology, 19, 45–49.
   PubMedGoogle Scholar
• Oosterhuis, H. J. (1989). The natural course of myasthenia gravis: A long term follow up study. Journal of Neurology, Neurosurgery, and Psychiatry, 52, 1121–1127.
   PubMed Web of Science ®Google Scholar
• Osserman, K. E., & Genkins, G. (1971). Studies in myasthenia gravis: Review of a twenty-year experience in over 1200 patients. The Mount Sinai Journal of Medicine, 38, 497–537.
   PubMed Web of Science ®Google Scholar
• Perlo, V. P., Poskanzer, D. C., Schwab, R. S., Viets, H. R., Osserman, K. E., & Genkins, G. (1966). Myasthenia gravis: Evaluation of treatment in 1,355 patients. Neurology, 16, 431–439.
   PubMed Web of Science ®Google Scholar
• Phillips, L. H., 2nd, Torner, J. C., Anderson, M. S., & Cox, G. M. (1992). The epidemiology of myasthenia gravis in central and western Virginia. Neurology, 42, 1888–1893.
   PubMed Web of Science ®Google Scholar
• Poulas, K., Tsibri, E., Kokla, A., Papanastasiou, D., Tsouloufis, T., Marinou, M., (2001). Epidemiology of seropositive myasthenia gravis in Greece. Journal of Neurology, Neurosurgery, and Psychiatry, 71, 352–356.
   PubMed Web of Science ®Google Scholar
• Somnier, F. E., Keiding, N., & Paulson, O. B. (1991). Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Archives of Neurology, 48, 733–739.
   PubMedGoogle Scholar
• Spurkland, A., Gilhus, N. E., Ronningen, K. S., Aarli, J. A., & Vartdal, F. (1991). Myasthenia gravis patients with thymus hyperplasia and myasthenia gravis patients with thymoma display different HLA associations. Tissue Antigens, 37, 90–93.
   PubMed Web of Science ®Google Scholar
• Treves, T. A., Rocca, W. A., & Meneghini, F. (1991). Epidemiology of Myasthenia Gravis. Boston, MA: CRC Press.
   Google Scholar
• Vincent, A., Bowen, J., Newsom-Davis, J., & McConville, J. (2003). Seronegative generalised myasthenia gravis: Clinical features, antibodies, and their targets. Lancet Neurology, 2, 99–106.
   PubMed Web of Science ®Google Scholar
• Vincent, A., & Leite, M. I. (2005). Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis. Current Opinion in Neurology, 18, 519–525.
   PubMed Web of Science ®Google Scholar
• Vincent, A., McConville, J., Farrugia, M. E., Bowen, J., Plested, P., Tang, T., (2003). Antibodies in myasthenia gravis and related disorders. Annals of the New York Academy of Sciences, 998, 324–335.
   PubMed Web of Science ®Google Scholar
• Vincent, A., & Newsom Davis, J. (1980). Anti-acetylcholine receptor antibodies. Journal of Neurology, Neurosurgery, and Psychiatry, 43, 590–600.
   PubMed Web of Science ®Google Scholar
• Vincent, A., & Newsom-Davis, J. (1985). Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. Journal of Neurology, Neurosurgery, and Psychiatry, 48, 1246–1252.
   PubMed Web of Science ®Google Scholar
• Vincent, A., Whiting, P. J., Schluep, M., Heidenreich, F., Lang, B., Roberts, A., (1987). Antibody heterogeneity and specificity in myasthenia gravis. Annals of the New York Academy of Sciences, 505, 106–120.
   PubMedGoogle Scholar
• Wing Lok AU MRCP (UK), A. D. A. F., Helen TL TJIA MMed, & FAMS, (2003). Myasthenia gravis in Singapore. Neurological Journal of Southeast Asia, 8, 35–40.
   Google Scholar
• Yamamoto, T., Vincent, A., Ciulla, T. A., Lang, B., Johnston, I., & Newsom-Davis, J. (1991). Seronegative myasthenia gravis: A plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Annals of Neurology, 30, 550–557.
   PubMedGoogle Scholar
• Yeh, J. H., Chen, W. H., Chiu, H. C., & Vincent, A. (2004). Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology, 62, 2131–2132.
   PubMedGoogle Scholar